GlassScriptPhysician profile
Nadia Hasan
NPI 1710549787
$1,969.75
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,421 · 2022: $529 · 2023: $18.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $383.25 | 2021-2022 | |
| Glaxosmithkline, LLC. | $266.56 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $263.55 | 2021-2022 | |
| Abbvie INC. | $244.50 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.24 | 2021-2022 | |
| Novo Nordisk INC | $166.48 | 2021-2022 | |
| Amgen INC. | $139.54 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $63.75 | 2021-2022 | |
| Pfizer INC. | $55.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.38 | 2021-2022 | |
| Astellas Pharma US INC | $31.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.33 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.53 | 2022 | |
| Eisai INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.